The safety profile through Week 16 atopic dermatitis patients aged 12 years and older with uncontrolled moderate-to-severe hand and/or foot involvement was consistent with the known safety profile of DUPIXENT in patients 6 months and older with uncontrolled, moderate‑to‑severe atopic dermatitis.1,2

The most common adverse reactions (incidence ≥1%) are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia.1,2